AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31797570 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (generic)
Number of subjects: 12
Study 31797570 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (branded)
Number of subjects: 12
Study 31256911 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalomedullary nail (Targon® PF or PFT)
Number of subjects: 1000
Study 31256911 — intervention group
Group type: COMPARATOR
Intervention: Sliding hip screw (SHS)
Number of subjects: 1000
Study 27422781 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (ClosureFAST™)
Number of subjects: 200
Study 27422781 — intervention group
Group type: COMPARATOR
Intervention: Endovenous laser ablation (980 nm diode laser)
Number of subjects: 200
Study 25782717 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (9 week open label trial)
Number of subjects: 58
Study 25782717 — intervention group
Group type: COMPARATOR
Intervention: Eszopiclone
Number of subjects: 58
Study 25782717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 23577643 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 458
Study 23577643 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin (Sita)
Number of subjects: 458
Study 21689394 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (10-14 sessions: 6-10 during pregnancy and 4-8 after delivery)
Number of subjects: 300
Study 21689394 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 300
Study 21689394 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy
Number of subjects: 300
Study 19690254 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidewire
Number of subjects: 200
Study 19690254 — intervention group
Group type: EXPERIMENTAL
Intervention: Slit endotracheal tube
Number of subjects: 200
Study 19690254 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck flexion with lateral neck pressure
Number of subjects: 200
Study 19690254 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 200
Study 16796078 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 130 mg/day
Number of subjects: 146
Study 16796078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 15648529 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Management Treatment (PMT) in the experimental group (E)
Number of subjects: 238
Study 15648529 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group untreated)
Number of subjects: 238
Study 11259986 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine 4 mg once daily for 8 days
Number of subjects: 18
Study 11259986 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg once daily alone
Number of subjects: 18
Study 9426081 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 2x100 microg via Turbuhaler
Number of subjects: 62
Study 9426081 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 100 microg via Turbuhaler
Number of subjects: 62
Study 9426081 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 50 microg via Turbuhaler
Number of subjects: 62
Study 9426081 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 100 microg via pMDI
Number of subjects: 62
Study 9426081 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 2x200 microg via pMDI
Number of subjects: 62
Study 9426081 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol via Turbuhaler vs pMDI
Number of subjects: 62
Study 8513955 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized progesterone (200 mg) under fasting conditions
Number of subjects: 15
Study 8513955 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized progesterone (100, 200, or 300 mg) under fasting conditions
Number of subjects: 15
Study 8513955 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized progesterone (200 mg) under nonfasting conditions
Number of subjects: 15
Study 8513955 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular progesterone (50 mg in oil)
Number of subjects: 15
Study 3103158 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg caffeine
Number of subjects: 19
Study 3103158 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg caffeine
Number of subjects: 19
Study 3103158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 28652090 — intervention group
Group type: EXPERIMENTAL
Intervention: PCPs aware of USPSTF recommendations for LDCT
Number of subjects: 250
Study 27486873 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox treatment (mean daily dose 11.8 ± 7.0 mg/kg, mean duration 16 months)
Number of subjects: 99
Study 24529600 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroFlo treatment
Number of subjects: 0
Study 22219335 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg twice daily for 1 week)
Number of subjects: 13
Study 19473822 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheese naturally rich in cis-9, trans-11 CLA (200 g/week)
Number of subjects: 10
Study 19473822 — intervention group
Group type: COMPARATOR
Intervention: Commercially available cheese (placebo)
Number of subjects: 10
Study 18693230 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home intervention involving occupational and physical therapy home instruction in problem solving, device use, energy conservation, safety, fall recovery, balance, and muscle strengthening.
Number of subjects: 319
Study 18693230 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 319
Study 18693230 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home intervention
Number of subjects: 319
Study 15897376 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin therapy
Number of subjects: 132
Study 15897376 — intervention group
Group type: COMPARATOR
Intervention: Conservative acne therapy
Number of subjects: 132
Study 12849654 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 222
Study 12849654 — intervention group
Group type: COMPARATOR
Intervention: Class I agents
Number of subjects: 222
Study 12849654 — intervention group
Group type: COMPARATOR
Intervention: Sotalol
Number of subjects: 222
Study 12675021 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/day for 3 years)
Number of subjects: 994
Study 12675021 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (any dose)
Number of subjects: 994
Study 12675021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 994
Study 8947071 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency breathing (LFB)
Number of subjects: 15
Study 8947071 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 15
Study 1782518 — intervention group
Group type: EXPERIMENTAL
Intervention: Table-top simulation, photographs of road situations, real-world sites near schools
Number of subjects: 0
Study 7272178 — intervention group
Group type: EXPERIMENTAL
Intervention: Caroxazone 200 mg three times daily
Number of subjects: 9
Study 7272178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 7272178 — intervention group
Group type: EXPERIMENTAL
Intervention: Caroxazone (after discontinuation)
Number of subjects: 9
Study 31513968 — intervention group
Group type: EXPERIMENTAL
Intervention: Syndromal anxious depression
Number of subjects: 1008
Study 31513968 — intervention group
Group type: EXPERIMENTAL
Intervention: HRSD anxious depression
Number of subjects: 1008
Study 31513968 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 1008
Study 31036468 — intervention group
Group type: EXPERIMENTAL
Intervention: Tucidinostat plus exemestane
Number of subjects: 365
Study 31036468 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus exemestane
Number of subjects: 365
Study 28017254 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ)
Number of subjects: 121
Study 28017254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 26313348 — intervention group
Group type: EXPERIMENTAL
Intervention: nano-calcium phosphate paste
Number of subjects: 40
Study 26313348 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 24140678 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel with low-dose aspirin (<150 mg)
Number of subjects: 12674
Study 24140678 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel with high-dose aspirin (≥150 mg)
Number of subjects: 12674
Study 24140678 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 12674
Study 21884007 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 36
Study 21884007 — intervention group
Group type: EXPERIMENTAL
Intervention: B-group vitamins (folic acid 1 mg, vitamin B12 0.4 mg, and B6 10 mg)
Number of subjects: 36
Study 21884007 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin and B-group vitamins combined
Number of subjects: 36
Study 19538242 — intervention group
Group type: COMPARATOR
Intervention: Metformin 1 g orally with a standard mixed meal (SMM)
Number of subjects: 10
Study 19538242 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1 g orally without a SMM (fasting)
Number of subjects: 10
Study 18085140 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicine cup group (n = 47) treated with cupping therapy using a self-made medicine cup with 45 degrees C Chinese herb solution.
Number of subjects: 140
Study 18085140 — intervention group
Group type: EXPERIMENTAL
Intervention: Water cup group (n = 47) treated with a cup with 45 degrees C water.
Number of subjects: 140
Study 18085140 — intervention group
Group type: COMPARATOR
Intervention: Empty cup group (n = 46) treated with a cup with nothing.
Number of subjects: 140
Study 15318859 — intervention group
Group type: EXPERIMENTAL
Intervention: Accepted donors (Group A)
Number of subjects: 4158
Study 15318859 — intervention group
Group type: COMPARATOR
Intervention: Deferred donors (Group B)
Number of subjects: 4158
Study 15505358 — intervention group
Group type: EXPERIMENTAL
Intervention: AngioJet rheolytic thrombectomy
Number of subjects: 0
Study 15505358 — intervention group
Group type: COMPARATOR
Intervention: Conventional primary angioplasty
Number of subjects: 0
Study 10598600 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% sevoflurane in 100% O2 (group SevoRAPID)
Number of subjects: 0
Study 10598600 — intervention group
Group type: EXPERIMENTAL
Intervention: 2%, 4%, 6%, and 7% sevoflurane in 100% O2 (group SevoINCR)
Number of subjects: 0
Study 10598600 — intervention group
Group type: COMPARATOR
Intervention: 1%, 2%, 3%, and 3.5% halothane in 50% N2O‐50% O2 (group HaloN2O)
Number of subjects: 0
Study 10598600 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% sevoflurane in 50% N2O‐50% O2 (group SevoN2O)
Number of subjects: 0
Study 8528851 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid i.v. injection of famotidine
Number of subjects: 105
Study 8528851 — intervention group
Group type: COMPARATOR
Intervention: Slow i.v. infusion of famotidine
Number of subjects: 105
Study 1778319 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular DTP vaccine (25 micrograms PT)
Number of subjects: 2
Study 1778319 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular DTP vaccine (8 micrograms PT)
Number of subjects: 2
Study 1778319 — intervention group
Group type: COMPARATOR
Intervention: Whole-cell DTP vaccine
Number of subjects: 2
Study 1778319 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular DTP vaccines (both doses)
Number of subjects: 2
Study 7213528 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (250 mg)
Number of subjects: 14
Study 7213528 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (390 mg)
Number of subjects: 14
Study 7213528 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (5 mg/kg) administered intravenously
Number of subjects: 14
Study 7213528 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (5 mg/kg) administered intravenously
Number of subjects: 14
Study 28485186 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab beta
Number of subjects: 1841
Study 28485186 — intervention group
Group type: COMPARATOR
Intervention: IM interferon beta-1a
Number of subjects: 1841
Study 26994623 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline (0.05%) plus intranasal steroid (budesonide 100 μg/spray)
Number of subjects: 50
Study 26994623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 25180876 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (40 mg twice a day for 2 weeks)
Number of subjects: 55
Study 25180876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 22056021 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus cetuximab
Number of subjects: 1121
Study 22056021 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 1121
Study 21123578 — intervention group
Group type: EXPERIMENTAL
Intervention: High threat condition (potentially harmful)
Number of subjects: 0
Study 21123578 — intervention group
Group type: COMPARATOR
Intervention: Low threat condition (entirely safe)
Number of subjects: 0
Study 17613279 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg, orally twice daily with meals for one month)
Number of subjects: 60
Study 17613279 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard therapeutic regimen)
Number of subjects: 60
Study 15701354 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 20
Study 15701354 — intervention group
Group type: COMPARATOR
Intervention: Waitlist condition (WL)
Number of subjects: 20
Study 12005153 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 33
Study 12005153 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 33
Study 9790395 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg rectal misoprostol
Number of subjects: 550
Study 9790395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 550
Study 8538974 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone support intervention (weekly calls throughout pregnancy)
Number of subjects: 131
Study 8538974 — intervention group
Group type: COMPARATOR
Intervention: Control group (no telephone support)
Number of subjects: 131
Study 31867655 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced nicotine content cigarettes (0.4, 2.4, 5.2, 15.8 mg/g)
Number of subjects: 169
Study 31867655 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced nicotine content cigarettes
Number of subjects: 169
Study 30287158 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline and olanzapine
Number of subjects: 57
Study 30287158 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 57
Study 26162521 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel (TG) 80 mg daily for 4 days
Number of subjects: 10
Study 24284442 — intervention group
Group type: EXPERIMENTAL
Intervention: W25 (25 g whey protein, 3.0 g leucine)
Number of subjects: 40
Study 24284442 — intervention group
Group type: EXPERIMENTAL
Intervention: W6 (6.25 g whey protein, 0.75 g leucine)
Number of subjects: 40
Study 24284442 — intervention group
Group type: EXPERIMENTAL
Intervention: W6+Low‐Leu (6.25 g whey protein supplemented to 3.0 g total leucine)
Number of subjects: 40
Study 24284442 — intervention group
Group type: EXPERIMENTAL
Intervention: W6+High‐Leu (6.25 g whey protein supplemented to 5.0 g total leucine)
Number of subjects: 40
Study 24284442 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAAs (6.25 g whey protein supplemented with leucine, isoleucine, and valine to 5.0 g total leucine)
Number of subjects: 40
Study 22871086 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegaptanib sodium 0.3 mg intravitreal injection
Number of subjects: 1586
Study 18823228 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan supplements (3 g per day for 14 days)
Number of subjects: 15
Study 18823228 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched control)
Number of subjects: 15
Study 17893438 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.6 mg/ml, maximum 16 mg) in a single dose
Number of subjects: 47
Study 17893438 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone (8‐10 mg/kg/day) in 4 equal doses for 2 days
Number of subjects: 47
Study 15502721 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 131
Study 15502721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 11684376 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal continuous hormonal replacement therapy (HRT)
Number of subjects: 60
Study 11684376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9596459 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of otitis media (OM) by physicians
Number of subjects: 21259
Study 9596459 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of upper respiratory infections (URI) by physicians
Number of subjects: 21259
Study 7888289 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg single dose)
Number of subjects: 0
Study 7888289 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg daily for 8 weeks)
Number of subjects: 0
Study 7888289 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (0.1 mg ml-1) in vitro
Number of subjects: 0
Study 7888289 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (small concentrations up to 0.19 micrograms ml-1) in vitro
Number of subjects: 0
Study 7888289 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (higher concentrations) in vitro
Number of subjects: 0
Study 3285878 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 120 mg/day
Number of subjects: 132
Study 3285878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 29119833 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonidegib
Number of subjects: 0
Study 28537581 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (5x10^9 colony‐forming units)
Number of subjects: 63
Study 28537581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 25380149 — intervention group
Group type: EXPERIMENTAL
Intervention: perindopril/amlodipine
Number of subjects: 1757
Study 25380149 — intervention group
Group type: COMPARATOR
Intervention: valsartan/amlodipine
Number of subjects: 1757
Study 23158043 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder surgeons evaluating full-thickness tears of the supraspinatus central tendon on MRI
Number of subjects: 40
Study 23158043 — intervention group
Group type: COMPARATOR
Intervention: Shoulder surgeons vs MSK radiologists evaluating full-thickness tears of the supraspinatus central tendon on MRI
Number of subjects: 40
Study 23158043 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder surgeons evaluating partial-thickness tears of the supraspinatus central tendon on MRI
Number of subjects: 40
Study 20197560 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler echocardiography
Number of subjects: 43
Study 20197560 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler echocardiography after unloading manipulations
Number of subjects: 43
Study 20197560 — intervention group
Group type: COMPARATOR
Intervention: Swan-Ganz catheterization
Number of subjects: 43
Study 18759767 — intervention group
Group type: EXPERIMENTAL
Intervention: PARMA 5 computer-assisted dosage
Number of subjects: 10421
Study 18759767 — intervention group
Group type: COMPARATOR
Intervention: Manual dosage by experienced medical staff
Number of subjects: 10421
Study 16176613 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lactalbumin diet
Number of subjects: 43
Study 16176613 — intervention group
Group type: COMPARATOR
Intervention: Casein (placebo)
Number of subjects: 43
Study 12732395 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol (E2)
Number of subjects: 43
Study 12732395 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E2)
Number of subjects: 43
Study 10372217 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 32
Study 10372217 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 32
Study 9082342 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterozygous carriers for Leiden mutation
Number of subjects: 50
Study 9082342 — intervention group
Group type: COMPARATOR
Intervention: Patients with idiopathic thromboembolic disease
Number of subjects: 50
Study 9082342 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 2069221 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic saline flush once a week
Number of subjects: 0
Study 2069221 — intervention group
Group type: COMPARATOR
Intervention: Heparin flush twice daily
Number of subjects: 0
Study 6429407 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional therapy with an EAA mixture containing tyrosine, increased valine, and decreased leucine proportions compared to normal recommendations.
Number of subjects: 0
Study 6429407 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with valine.
Number of subjects: 0
Study 6429407 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet supplemented with EAA mixture.
Number of subjects: 0
Study 31666828 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (1 mg)
Number of subjects: 33
Study 31666828 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (35 μg [0.5 μg/kg])
Number of subjects: 33
Study 31666828 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Neostigmine (0.5 mg) and Dexmedetomidine (35 μg)
Number of subjects: 33
Study 31666828 — intervention group
Group type: COMPARATOR
Intervention: Control (Lidocaine 1.5% + Triamcinolone 40 mg/ml)
Number of subjects: 33
Study 29892252 — intervention group
Group type: COMPARATOR
Intervention: three funny things intervention (humor-based PPI)
Number of subjects: 736
Study 29892252 — intervention group
Group type: COMPARATOR
Intervention: five different humor-based interventions
Number of subjects: 736
Study 29892252 — intervention group
Group type: COMPARATOR
Intervention: three funny things intervention
Number of subjects: 736
Study 29892252 — intervention group
Group type: COMPARATOR
Intervention: humor-based interventions
Number of subjects: 736